Viridian Therapeutics Inc (STU:1S1)
€ 19.9 -0.30 (-1.49%) Market Cap: 2.26 Bil Enterprise Value: 1.71 Bil PE Ratio: 0 PB Ratio: 4.42 GF Score: 52/100

Viridian Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript

Jun 09, 2026 / 08:00PM GMT
Release Date Price: €14.1 (+3.68%)
Richard Law
Goldman Sachs Group Inc - Analyst

All right. Good afternoon. Let's kick off our next session. It is my pleasure to host Viridian Therapeutics. And with me, we have Steve Mahoney and Shan Wu, CEO and CBO of the company.

So a lot to talk about, very, very exciting year. But before we go do it, I'm going to kick it off to Steve and Shan for opening remarks.

Stephen Mahoney;Principal Executive Officer
Viridian Therapeutics Inc - President, Chief Executive Officer, Director

()

Yeah. Thanks, Rich. Thanks for having us. We appreciate it. We are on the verge of commercial approval. We have a PDUFA date of June 30, so very short time period until we expect to be on the market. All of our regulatory interactions have been consistent and positive and give us a lot of confidence going into that PDUFA date. We are right on track with everything.

So that's exciting. We can talk about launch dynamics and that type of thing in more detail as we go. We obviously also had our top-line readout from our subcutaneous studies, REVEAL

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot